An Update on Systemic Treatment Options in Advanced Melanoma

PROGRAM CE18
RELEASE DATE: JUNE 15, 2011 • EXPIRATION DATE: JUNE 15, 2012
ESTIMATED TIME TO COMPLETE: 1.0 HOUR

Download PDF

Click here to complete the posttest and obtain a CE certificate online

STATEMENT OF NEED
Patients with metastatic melanoma historically have had few therapeutic options, but there have been recent advances in immunotherapy and the development of novel BRAF- and KIT-targeted agents for those with stage IV disease. This year ipilimumab, an immunotherapy monoclonal antibody, was FDA-approved for late-stage metastatic melanoma. Nurses now need to understand how these agents work, their efficacy, and their adverse event profiles. In addition, nurses will need to comprehend better the molecular changes that occur in relation to certain melanomas.

TARGET AUDIENCE
Advanced practice nurses, registered nurses, and other interested healthcare professionals, especially those caring for cancer patients

LEARNING OBJECTIVES
After completing this activity, the reader should be able to:

• Compare/contrast therapeutic options for patients with metastatic melanoma.
• Discuss efficacy rates and adverse event profiles for newly approved agents and those in the late-stage pipeline.

CONTINUING NURSING EDUCATION ACCREDITATION AND CONTACT HOURS STATEMENT
Science Care is approved by the California Board of Registered Nursing, Provider number 15559, for 1.0 Contact hour.

METHOD OF PARTICIPATION

1. Read the article in its entirety
2. Select “Click here to complete the posttest and obtain a CE certificate online”
3. Complete and submit the CE posttest and CE Activity Evaluation
4. Print your Certificate of Credit

This activity is provided free of charge to participants.

FACULTY DISCLOSURES
As a provider accredited by the California Board of Registered Nursing, Science Care must ensure balance, independence, objectivity, and scientific rigor in all its activities. All course directors, faculty, planners, and any other individual in a position to control the content of this educational activity are required to disclose to the audience any relevant financial relationships with any commercial interest. Science Care must determine if the faculty’s relationships may influence the educational content with regard to exposition or conclusion and resolve any conflicts of interest prior to the commencement of the educational activity.

Disclosures are as follows:

• Dawn Lagrosa has nothing to disclose.
• Christin Melton has nothing to disclose.
• Suzanne McGettigan, MSN, CRNP, APRN-BC, AOCN, is on the speakers’ bureau for Bristol-Myers Squibb and Merck and Co.

The staff of Science Care have nothing to disclose.

UNLABELED OR UNAPPROVED USE OF DRUGS OR DEVICES
It is the policy of Science Care to require the disclosure of all references to unlabeled or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this CE activity may contain reference( s) to unlabeled or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

DISCLAIMER
The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of Science Care or Green Hill Healthcare Communications, LLC.

COPYRIGHT STATEMENT
Copyright © 2011 Science Care. All rights reserved.